文献速递胸部肿瘤

EGFR突变NSCLC中PACC突变与20外显子插入的诊疗进展

P-Loop/αC-Helix Compressing Mutations and Exon 20 Insertions in EGFR-Mutant NSCLC: A Rapidly Evolving Therapeutic Landscape.
PubMed 文献 · J Clin Oncol · 2026-09-14

本叙述性综述聚焦EGFR PACC突变与20外显子插入(ex20ins)两类非经典突变NSCLC,梳理结构生物学、临床试验及真实世界证据。PACC变异中阿法替尼活性最一致,复合突变可从奥希替尼等三代TKIs获益;ex20ins中amivantamab及突变选择性TKIs显示有临床意义的活性,WU-KONG28确立sunvozertinib一线优于铂类-培美曲塞。耐药机制异质,包括C797S、E709K等靶内突变及MET等旁路途径。

要点

  • PACC变异如G719X、S768I、E709X、L747X对阿法替尼活性最一致。
  • PACC复合突变常从奥希替尼等三代TKIs获得更大获益。
  • ex20ins中sunvozertinib一线优于铂类-培美曲塞(WU-KONG28)。

核心结论

  • EGFR PACC与ex20ins是区别于经典突变的激酶域突变亚组,其结构与对现有TKIs的响应性不同。

研究设计与样本

  • 叙述性综述,汇总结构生物学、临床试验数据及真实世界证据,聚焦PACC与ex20ins EGFR突变NSCLC的治疗选择、耐药机制及潜在治疗序贯。

主要发现

  • PACC变异(G719X、S768I、E709X、L747X)中第二代TKI阿法替尼提供最一致的活性。
  • PACC复合突变常从第三代TKIs(包括奥希替尼)获得更大获益。
  • firmonertinib与enozertinib等突变选择性抑制剂正作为PACC突变的专用选择进行探索。
  • ex20ins中amivantamab及sunvozertinib、zipalertinib、firmonertinib等突变选择性TKIs显示有临床意义的活性。
  • WU-KONG28确立sunvozertinib一线优于铂类-培美曲塞。

关键数值与推荐

  • PACC变异如G719X、S768I、E709X、L747X对阿法替尼活性最一致。
  • PACC复合突变常从奥希替尼等三代TKIs获得更大获益。
  • WU-KONG28显示sunvozertinib一线优于铂类-培美曲塞。

临床怎么用

  • PACC变异可优先考虑阿法替尼,复合突变可考虑奥希替尼等三代TKIs。
  • ex20ins一线可考虑sunvozertinib(基于WU-KONG28)或amivantamab等突变选择性药物。
  • 耐药后需评估C797S、E709K等靶内突变及MET等旁路机制以指导后续治疗。

局限性

  • 为叙述性综述,非系统评价,未提供定量合并分析。
  • 新兴突变选择性抑制剂的证据多来自早期探索,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A structure-function classification has defined epidermal growth factor receptor (EGFR) P-loop/αC-helix compressing (PACC) mutations and exon 20 insertions (ex20ins) as distinct subsets of kinase domain EGFR alterations. Lung cancers harboring those mutations display reduced sensitivity to EGFR tyrosine kinase inhibitors (TKIs) currently approved for EGFR classical sensitizing mutations and have often been managed with chemotherapy. METHODS: This narrative review describes structural biology, clinical trial data, and real-world evidence on PACC and ex20ins EGFR-mutant non-small cell lung cancer, with a focus on current treatment options, emerging resistance mechanisms, and the potential treatment sequencing. RESULTS: For EGFR PACC variants such as G719X, S768I, E709X, and L747X, second-generation TKIs such as afatinib provide the most consistent activity, whereas common-plus-PACC compound mutations often derive greater benefit from third-generation TKIs, including osimertinib. Emerging mutant-selective inhibitors, including firmonertinib and enozertinib, are now being explored as dedicated options for PACC mutations. For EGFR ex20ins, amivantamab and mutant-selective TKIs such as sunvozertinib, zipalertinib, and firmonertinib have demonstrated clinically meaningful activity, with WU-KONG28 establishing first-line superiority of sunvozertinib over platinum-pemetrexed. Across both these subsets, resistance remains heterogeneous, encompassing on-target mutations, including C797S and E709K, as well as MET and other bypass track pathways. CONCLUSION: EGFR PACC and ex20ins are established subgroups of kinase domain mutations, distinct from classical mutations, due to structure and responsiveness to available TKIs.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Monaca F, Randulfe I, Heymach JV, et al. P-Loop/αC-Helix Compressing Mutations and Exon 20 Insertions in EGFR-Mutant NSCLC: A Rapidly Evolving Therapeutic Landscape. J Clin Oncol. 2026. PMID: 42735369. doi:10.1200/JCO-26-00556

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。